This molecule was tested on epidermoid and prostate cancer cells known to express amplification of EGFR, and proved to be highly active in vitro with IC50 (inhibitory concentration: 50% inhibition) lower than 1ng/ml and doubling the mouse survival time in murine xenograft models [79,80]. This evidence concerns the gene EGFR and prostate carcinoma.